Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 6 de 6
Filtrar
Más filtros










Base de datos
Intervalo de año de publicación
1.
Biodivers Data J ; (7): e32555, 2019.
Artículo en Inglés | MEDLINE | ID: mdl-30740026

RESUMEN

BACKGROUND: Clavicornaltica is a genus of very small flea beetles living in the leaf litter layer of Asian forests, easily sampled with Winkler extraction. The genus is presumably very rich in species, but their taxonomy is hampered by their small size and morphological uniformity. NEW INFORMATION: On a 'taxon expedition'-style field course at Kuala Belalong Field Studies Centre in Brunei Darussalam (Borneo), a new species, Clavicornaltica belalongensis n. sp., was discovered and taxonomically treated by the course participants. We also present the first DNA barcodes for the genus.

2.
BMC Public Health ; 17(1): 881, 2017 11 15.
Artículo en Inglés | MEDLINE | ID: mdl-29141600

RESUMEN

BACKGROUND: Patients with TB have diverse and often challenging clinical and social needs that may hamper successful treatment outcomes. Understanding the need for additional support during treatment (enhanced case management, or ECM) is important for workforce capacity planning. North West England TB Cohort Audit (TBCA) has introduced a 4-level ECM classification system (ECM 0-3) to quantify the need for ECM in the region. This study describes the data from the first 2 years of ECM classification. METHODS: Data collected between April 2013 and July 2015 were used to analyse the proportions of patients allocated to each ECM level and the prevalence of social and clinical factors indicating need for ECM. Single variable and multivariable logistic regression models were constructed to examine the association between ECM level and treatment outcome. RESULTS: Of 1714 notified cases 99.8% were assigned an ECM level: 31% ECM1, 19% ECM2 and 14% ECM3. The most common factors indicating need for ECM were language barriers (20.3%) and clinical complexity (16.9%). 1342/1493 (89.9%) of drug-sensitive, non-CNS cases completed treatment within 12 months. Patients in ECM2 and 3 were less likely to complete treatment at 12 months than patients in ECM0 (adjusted OR 0.47 [95% CI 0.27-0.84] and 0.23 [0.13-0.41] respectively). CONCLUSIONS: Use of TBCA to quantify different levels of need for ECM is feasible and has demonstrated that social and clinical complexity is common in the region. Results will inform regional workforce planning and assist development of innovative methods to improve treatment outcomes in these vulnerable groups.


Asunto(s)
Manejo de Caso/organización & administración , Auditoría Médica , Evaluación de Necesidades , Tuberculosis/terapia , Adulto , Estudios de Cohortes , Inglaterra , Femenino , Humanos , Masculino , Persona de Mediana Edad , Resultado del Tratamiento
3.
BMC Infect Dis ; 17(1): 569, 2017 08 15.
Artículo en Inglés | MEDLINE | ID: mdl-28810833

RESUMEN

BACKGROUND: Rotavirus was the leading cause of acute gastroenteritis (AGE) in infants and young children prior to the introduction of routine vaccination. Since 2006 there have been two licensed vaccines available; with successful clinical trials leading the World Health Organization to recommend rotavirus vaccination for all children worldwide. In order to inform immunisation policy we have conducted a systematic review and meta-analysis of observation studies to assess population effectiveness against acute gastroenteritis. METHODS: We systematically searched PubMed, Medline, Web of Science, Cinhal and Academic Search Premier and grey literature sources for studies published between January 2006 and April 2014. Studies were eligible for inclusion if they were observational measuring population effectiveness of rotavirus vaccination against health care attendances for rotavirus gastroenteritis or AGE. To evaluate study quality we use used the Newcastle-Ottawa Scale for non-randomised studies, categorising studies by risk of bias. Publication bias was assessed using funnel plots. If two or more studies reported a measure of vaccine effectiveness (VE), we conducted a random effects meta-analysis. We stratified analyses by World Bank country income level and used study quality in sensitivity analyses. RESULTS: We identified 30 studies, 19 were from high-income countries and 11 from middle-income countries. Vaccine effectiveness against hospitalization for laboratory confirmed rotavirus gastroenteritis was highest in high-income countries (89% VE; 95% CI 84-92%) compared to middle-income countries (74% VE; 95% CI 67-80%). Vaccine effectiveness was higher for those receiving the complete vaccine schedule (81% VE; 95% CI 75-86%) compared to partial schedule (62% VE; 95% CI 55-69%). Two studies from high-income countries measured VE against community consultations for AGE with a pooled estimate of 40% (95% CI 13-58%; 2 studies). CONCLUSIONS: We found strong evidence to further support the continued use of rotavirus vaccines. Vaccine effectiveness was similar to that reported in clinical trials for both high and middle-income countries. There is limited data from Low income settings at present. There was lower effectiveness against milder disease. Further studies, should continue to report effectiveness against AGE and less-severe rotavirus disease because as evidenced by pre-vaccine introduction studies this is likely to contribute the greatest burden on healthcare resources, particularly in high-income countries.


Asunto(s)
Gastroenteritis/prevención & control , Infecciones por Rotavirus/prevención & control , Vacunas contra Rotavirus/uso terapéutico , Países Desarrollados/estadística & datos numéricos , Países en Desarrollo/estadística & datos numéricos , Gastroenteritis/epidemiología , Gastroenteritis/virología , Hospitalización/estadística & datos numéricos , Humanos , Esquemas de Inmunización , Lactante , Estudios Observacionales como Asunto , Infecciones por Rotavirus/epidemiología , Vacunación/estadística & datos numéricos , Vacunas Atenuadas/uso terapéutico
4.
J Econ Entomol ; 107(3): 1284-91, 2014 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-25026694

RESUMEN

Experiments were performed to determine the efficacy of a single aerosol application of the insecticides methoprene and piperonyl butoxide-synergized pyrethrin, alone or in combination, and the insecticide carrier, Isopar M, against Tribolium castaneum (Herbst), the red flour beetle. The initial test exposed adults to insecticide treatments and placed male/female pairs in flour. All adults exposed to synergized pyrethrin were knocked down for at least 24 h after exposure but they recovered. High adult survival and similar average numbers of living F1 progeny were produced regardless of treatment exposure. In a separate test, insecticide treatments were directly applied to newly laid eggs, which resulted in the suppression of egg hatch. Synergized pyrethrin was the most effective insecticide (P < or = 0.001) for suppressing egg hatch. The effect of flour on insecticide activity to eggs and consequent insect development was also evaluated. An amount of 0.01 g of flour in the exposure arena, 62-cm2 area, was not sufficient for individuals to develop beyond the early larval stages, regardless of the treatment. As the flour amount in the arena increased from 1 to 5 g, the number of eggs that could develop to the adult stage increased, but this number was significantly lower in the insecticide treatments than in the control or carrier treatments. The results of the later tests indicate a high efficacy of the insecticides alone or in combination on T. castaneum egg hatch and development to the adult stage.


Asunto(s)
Insecticidas/farmacología , Hormonas Juveniles/farmacología , Metopreno/farmacología , Piretrinas/farmacología , Tribolium/efectos de los fármacos , Aerosoles , Animales , Femenino , Harina/análisis , Larva/efectos de los fármacos , Larva/crecimiento & desarrollo , Masculino , Óvulo/efectos de los fármacos , Óvulo/crecimiento & desarrollo , Reproducción/efectos de los fármacos , Tribolium/crecimiento & desarrollo
5.
J Insect Physiol ; 52(8): 786-94, 2006 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-16806257

RESUMEN

The storage of large quantities of juvenile hormone (JH) in male abdomens is a phenomenon known from some species of moths. Juvenile hormone, stored in male accessory sex glands (ASG), may be transferred to the female during copulation, but the physiological significance of the JH transfer remains unclear. Here, using the moth Heliothis virescens as a model, we show that JH transferred from male to the promiscuous female promotes JH synthesis and egg development in the female. We propose that this explains the functional significance of JH transfer in species that exhibit last male sperm precedence, and that this hormone acts as a bioactive substance which the first male to mate uses for co-opting and regulating the female's gonadotropic mechanisms, thereby ensuring that despite last male sperm precedence he will sire a significant number of viable offspring.


Asunto(s)
Copulación/fisiología , Hormonas Juveniles/fisiología , Mariposas Nocturnas/fisiología , Animales , Femenino , Masculino , Espermatozoides/fisiología
6.
Obstet Gynecol ; 99(3): 439-44, 2002 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-11864671

RESUMEN

OBJECTIVE: To evaluate oral misoprostol use before office endometrial biopsy. METHODS: Forty-two nonpregnant women aged 35-77 years were randomized to a prospective, double-blind study to receive either 400 microg oral misoprostol or placebo 3 hours before office endometrial biopsy. Misoprostol effects were assessed by 1) cervical resistance, 2) ease of performing the endometrial biopsy, 3) success rate of obtaining an endometrial biopsy, 4) pain intensity associated with the endometrial biopsy, and 5) adverse clinical side effects. RESULTS: Patients in the misoprostol group experienced significantly (P <.01) more pain associated with the endometrial biopsy. The observed power to detect this difference in misoprostol-placebo comparison using the Wilcoxon rank sum test at 0.05 level of significance is 89%. In addition, significantly (P <.05) more patients had the adverse side effect of uterine cramping at 1.5 hours after medication ingestion in the misoprostol group. The observed power to detect this difference is 98%. There were no differences between the misoprostol and placebo groups in cervical resistance, ease of performing the biopsy, success rate for obtaining an endometrial biopsy, or adverse side effects at 3 hours post medication ingestion. CONCLUSION: Oral misoprostol 400 microg caused more uterine cramping and pain in nonpregnant women undergoing office endometrial biopsy when given 3 hours before biopsy attempt. No other cervical effects were noted.


Asunto(s)
Biopsia , Cuello del Útero/efectos de los fármacos , Endometrio/patología , Misoprostol/administración & dosificación , Procedimientos Quirúrgicos Ambulatorios , Método Doble Ciego , Femenino , Humanos , Persona de Mediana Edad , Misoprostol/uso terapéutico , Dolor/inducido químicamente , Premedicación , Estudios Prospectivos , Factores de Tiempo , Contracción Uterina/efectos de los fármacos
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...